Project Grant R21CA304638
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $422K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $421,685 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center, effective August 1, 2025, through July 31, 2027. This award supports pan-cancer analysis of convergent immunoglobulins from tumor-infiltrating B cells (TIL-B), with the primary deliverable being the identification and characterization of shared B cell receptors (BCR) and antibodies across...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $706,739 Project Grant to The University of Texas MD Anderson Cancer Center on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the molecular mechanisms of immunotherapy-associated myocarditis. This five-year research initiative (through May 31, 2031) addresses a critical clinical challenge: immune checkpoint inhibitor (ICI) treatments, while effective in cancer therapy, can trigger...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $136,270 project grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective June 1, 2026, through May 31, 2031. The award funds research aimed at dissecting the mechanisms by which messenger ribonucleic acid (mRNA) vaccines encoding non-tumor antigens initiate antitumor immunity in combination with immune checkpoint inhibitors (ICIs). The...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $163,310 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) on September 12, 2025, with a completion date of September 11, 2027. This award supports development of a multimodality biomarker platform designed to predict patient response to neoadjuvant immunotherapy and radiotherapy in melanoma, with a specific focus on mucosal melanoma subtypes that...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $432,134 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on June 5, 2025, with a completion date of May 31, 2027. This grant funds research into IL13RA2-targeted radioimmunotherapy (RIT) for glioblastoma, an aggressive primary brain tumor with poor prognosis. The research focuses on developing and evaluating therapeutic approaches that...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $669,540 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. This five-year research initiative investigates the role of the CD24 ligand in early lung cancer development, immune evasion, and response to KRAS-targeted therapy in KRAS-mutant lung adenocarcinomas (KM-LUADs). The research builds on...